Business Context and Reporting Period
Company: Omeros Corp (Biopharmaceutical, Development Stage)
Filing Type: Form 10-Q
Period Ended: September 30, 2010
Overview: Omeros is a clinical-stage biopharmaceutical company focused on inflammation and central nervous system disorders. Its lead platform, PharmacoSurgery, aims to improve outcomes in surgical procedures. The company has no approved products and relies on grant funding and capital markets for operations.
Key Financial Metrics
| Metric (in thousands) | 9 Months Ended Sep 30, 2010 | 9 Months Ended Sep 30, 2009 |
|---|---|---|
| Grant Revenue | $1,129 | $1,010 |
| Net Loss | $(22,020) | $(15,507) |
| Net Loss Per Share (Basic/Diluted) | $(1.03) | $(5.29) |
| Cash & Cash Equivalents (Sep 30, 2010) | $2,796 | $820 (Dec 31, 2009) |
| Short-term Investments (Sep 30, 2010) | $31,715 | $59,485 (Dec 31, 2009) |
| Total Liquidity (Cash + Investments) | $34,511 | $60,305 (Dec 31, 2009) |
| Notes Payable (Total) | $8,940 | $12,758 (Dec 31, 2009) |
| Accumulated Deficit | $(140,356) | $(118,336) (Dec 31, 2009) |
Material Changes vs. Prior Period
- Revenue: Grant revenue increased slightly to $1.1 million for the nine months ended September 30, 2010, compared to $1.0 million in the prior year period, driven by NIH grants.
- Operating Expenses: Total operating expenses rose to $22.7 million from $16.5 million. Research and Development (R&D) expenses increased to $16.5 million (from $12.3 million) due to higher clinical trial costs and one-time payments for license agreements (Helion and Affitech). General and Administrative (G&A) expenses increased to $6.2 million (from $4.2 million) due to public company costs.
- Liquidity: Total cash and short-term investments decreased from $60.3 million at year-end 2009 to $34.5 million at September 30, 2010. This reduction was primarily due to the sale of mortgage-backed securities and the shift to cash equivalents, alongside operating cash burn.
- Debt: The current portion of notes payable decreased significantly from $4.9 million to $67 thousand as the company reclassified debt to long-term following a refinancing agreement executed in October 2010 (subsequent event).
Guidance, Outlook, and Risks
- Outlook: Management expects net losses to increase in 2010 and beyond as clinical trials advance. The company anticipates no product revenue until at least 2012. Cash on hand is projected to fund operations for at least the next 12 months.
- Subsequent Events (Post-Sept 30, 2010):
- Funding: Received $20.0 million from Vulcan Inc. and a $5.0 million grant from the State of Washington (LSDF) for the GPCR program.
- Debt Refinancing: Entered a $20.0 million facility with Oxford Finance Corporation, borrowing $10.0 million to repay the prior BlueCrest lender in full.
- Acquisition: Exercised option to acquire GPCR technology assets from Patobios Limited for approximately $10.8 million CAD.
- Risks:
- Clinical Success: Heavy reliance on the success of the lead candidate OMS103HP (Phase 3 for ACL surgery). Failure to demonstrate efficacy or obtain FDA approval would be material.
- Liquidity: Continued need for capital raises; failure to secure funding could force delays in R&D.
- Legal: Ongoing litigation with former CFO Richard J. Klein regarding alleged False Claims Act violations and wrongful termination.
- Regulatory: FDA scrutiny regarding the design of clinical trials and the combination drug policy for OMS103HP.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $34.5 million liquidity position against the projected burn rate, considering the upcoming $10.8 million CAD acquisition payment.
- Clinical Milestones: Monitor the timeline for the release of Phase 3 results for OMS103HP (expected Q1 2011) and FDA feedback on trial design.
- Debt Covenants: Review the terms of the new Oxford Finance agreement, specifically the interest-only period ending October 2011 and the "material adverse change" default clause.
- Legal Exposure: Assess the potential financial impact of the lawsuit filed by former CFO Richard J. Klein.
- Grant Revenue Recognition: Confirm the timing of revenue recognition for the new Vulcan and LSDF funding, which is tied to expense incurrence rather than upfront cash receipt.